免疫学
医学
免疫疗法
免疫球蛋白E
效应器
变应原免疫治疗
免疫系统
疾病
先天性淋巴细胞
过敏
过敏原
下调和上调
免疫
生物
抗体
内科学
基因
生物化学
作者
Roxana Silvia Bumbăcea,Rama Boustani,Carmen Panaitescu,Laura Haidar,Maria Roxana Buzan,Dragoș Bumbăcea,Alexandru Laculiceanu,Cătălina Cojanu,Daniela Spânu,Ioana Agache
出处
期刊:Immunotherapy
[Future Medicine]
日期:2022-04-13
卷期号:14 (8): 627-638
被引量:16
标识
DOI:10.2217/imt-2021-0325
摘要
Allergen immunotherapy (AIT) is considered the only disease-modifying treatment available at present for allergic disorders. Its main benefits include improvement of symptoms, decreased need for pharmacotherapy, prevention of new sensitizations and sustained effect after AIT completion. The key pillars of AIT-induced tolerance include a shift from Th2 to Th1 response, an increase of regulatory T and B cells, pro-inflammatory effector cell downregulation and IgE suppression, in addition to IgG4, IgA and IgD induction. AIT may also induce trained immunity, characterized by a durable decrease in group 2 of innate lymphoid cells (ILCs) and increased ILC1 and ILC3s. Understanding the immune mechanisms of AIT is essential for validating biomarkers for the prediction of AIT response and for achieving AIT success.
科研通智能强力驱动
Strongly Powered by AbleSci AI